neurotoxin

Bonti Announces Results of Phase 2a Scar Reduction Clinical Study

EB-001A Clinical Trial Results

Bonti, a privately held, clinical-stage biotechnology company, announced topline results of its SHINE-1 (Scar Healing Improvement with Neurotoxin E) Phase 2a clinical trial, which evaluated the company’s EB-001A for scar reduction following Mohs surgery. EB-001, the active ingredient in EB-001A, is a novel botulinum neurotoxin serotype E (BoNT/E) with a unique clinical profile, characterized by a faster onset of action (within 24 hours) and a shorter duration of activity (two to four weeks) compared to botulinum neurotoxin serotype A (BoNT/A) products.

Additive Effects

Research confirms that combining neurotoxin with hyaluronic acid fillers can enhance and prolong desired effects, but more study is needed to understand the mechanisms of action.
Additive Effects

A recent study from researchers at Ondokuz Mayis University, Samsun, Turkey, published in Plastic and Reconstructive Surgery (January 2016), concluded that combination treatment with botulinum toxin type A (BTX-A) and hyaluronic acid (HA) fillers slowed the degradation of the filler.

Considerations for Achieving a Natural Look

Considerations for Achieving a Natural Look

In an article published in JAMA Facial Plastic Surgery (November/December 2015), Steven H. Dayan, MD, and Nazanin Ashourian, PhD, posit that plastic surgeons should examine kinetic models vs. static images to achieve more natural-looking cosmetic procedure outcomes. For example, too much filler in the cheek can interfere with the patient’s smile—something that is easily identifiable when looking at a patient’s face in motion.

Beyond Relaxing Lines

The growing options and indications for botulinum toxin type A suggest this well-established tool will continue to dominate aesthetic medicine.
Beyond Relaxing Lines

Botulinum toxin type A (BTX-A) formulations such as Botox (Allergan), Dysport (Galderma) and Xeomin (Merz) have moved well beyond their accepted roles as temporary erasers of glabellar lines, forehead rhytides and crow’s feet. Today, they are routinely employed all over the face and neck, and are being investigated for an impressive array of new indications.

Botulinum Toxin Increases Skin Elasticity and Pliability

Botulinum Toxin Increases Skin Elasticity and Pliability

In an effort to better understand the mechanism of action of onabotulinum toxin A on skin elasticity, researchers James P. Bonaparte, MD, MSc, FRCSC, and David Ellis, MD, FRCSC, conducted a study in which 48 women (mean age 55.2 years) underwent botulinum toxin injections for mild wrinkles in the glabella and around the eyes. The patients were assessed at baseline and after injection at two weeks, two months, three months and four months to measure skin pliability, elastic recoil and the ratio of viscoelastic resistance to elastic resistance.